Former Vice Premier Tsai Ing-wen (蔡英文) and AIDS research pioneer David Ho (何大一) will lead a new biotech company that will be jointly owned by the government and private investors to speed up the research and development of AIDS drugs, the nation's top economic planner said yesterday.
Ho Mei-yueh (何美玥), chairwoman of the Council for Economic Planning and Development, said the state-owned National Development Fund (NDF) would help finance the establishment of TaiMed Biologics Co (宇昌生技), which is planning to raise US$50 million in capital. Mo said the NDF plans to hold a 40 percent share in the company.
The government has authorized Tsai to assume the chairmanship and David Ho, a Taiwan-born AIDS expert and director of the New York-based Aaron Diamond AIDS Research Center, would serve as a co-founder of TaiMed Biologics, which would be a subsidiary of TaiMed Inc (台懋公司), a Taiwan-based biotech firm, Ho said.
Noting that TaiMed Biologics has gained patent authorization from US-based Genentech Inc for its lead clinical product, TNX-355, a potential treatment for HIV and AIDS patients, Ho said it marks a breakthrough in Taiwan's biotech industry.
She said the US company reported positive results in a Phase 2 clinical trial of TNX-355 and that a Phase 2b trial is expected to be conducted in the fourth quarter of this year in the US, Europe and South America.
TaiMed Biologics will be located in the Hsinchu Biomedical Park (新竹生醫園區) and will be the first enterprise to be set up in the park.
Other members of the TaiMed Biologics board of directors include Academia Sinica President Wong Chi-huey (翁啟惠), Lee Yuan-tseh (李遠哲), a Nobel laureate and former president of the Academic Sinica and Chen Lan-bo (陳良博), founder of Synta Pharmaceuticals Corp, a biopharmaceutical company.
CHIP RACE: Three years of overbroad export controls drove foreign competitors to pursue their own AI chips, and ‘cost US taxpayers billions of dollars,’ Nvidia said China has figured out the US strategy for allowing it to buy Nvidia Corp’s H200s and is rejecting the artificial intelligence (AI) chip in favor of domestically developed semiconductors, White House AI adviser David Sacks said, citing news reports. US President Donald Trump on Monday said that he would allow shipments of Nvidia’s H200 chips to China, part of an administration effort backed by Sacks to challenge Chinese tech champions such as Huawei Technologies Co (華為) by bringing US competition to their home market. On Friday, Sacks signaled that he was uncertain about whether that approach would work. “They’re rejecting our chips,” Sacks
Taiwan’s long-term economic competitiveness will hinge not only on national champions like Taiwan Semiconductor Manufacturing Co. (TSMC, 台積電) but also on the widespread adoption of artificial intelligence (AI) and other emerging technologies, a US-based scholar has said. At a lecture in Taipei on Tuesday, Jeffrey Ding, assistant professor of political science at the George Washington University and author of "Technology and the Rise of Great Powers," argued that historical experience shows that general-purpose technologies (GPTs) — such as electricity, computers and now AI — shape long-term economic advantages through their diffusion across the broader economy. "What really matters is not who pioneers
BUBBLE? Only a handful of companies are seeing rapid revenue growth and higher valuations, and it is not enough to call the AI trend a transformation, an analyst said Artificial intelligence (AI) is entering a more challenging phase next year as companies move beyond experimentation and begin demanding clear financial returns from a technology that has delivered big gains to only a small group of early adopters, PricewaterhouseCoopers (PwC) Taiwan said yesterday. Most organizations have been able to justify AI investments through cost recovery or modest efficiency gains, but few have achieved meaningful revenue growth or long-term competitive advantage, the consultancy said in its 2026 AI Business Predictions report. This growing performance gap is forcing executives to reconsider how AI is deployed across their organizations, it said. “Many companies
TAIWAN VALUE CHAIN: Foxtron is to fully own Luxgen following the transaction and it plans to launch a new electric model, the Foxtron Bria, in Taiwan next year Yulon Motor Co (裕隆汽車) yesterday said that its board of directors approved the disposal of its electric vehicle (EV) unit, Luxgen Motor Co (納智捷汽車), to Foxtron Vehicle Technologies Co (鴻華先進) for NT$787.6 million (US$24.98 million). Foxtron, a half-half joint venture between Yulon affiliate Hua-Chuang Automobile Information Technical Center Co (華創車電) and Hon Hai Precision Industry Co (鴻海精密), expects to wrap up the deal in the first quarter of next year. Foxtron would fully own Luxgen following the transaction, including five car distributing companies, outlets and all employees. The deal is subject to the approval of the Fair Trade Commission, Foxtron said. “Foxtron will be
RSS